Acasti Pharma Announces Patents for GTX-104 in Europe, GTX-102 in the U.S. and GTX-101 in Japan

On Mar 22, 2022

Acasti Pharma Inc. announces the following patent notifications and awards relating to the Company’s three lead drug candidates:

The European Patent Office has provided notice of intention to grant the Company’s composition of matter patent for GTX-104, an IV formulation of nimodipine for use in the treatment of patients with subarachnoid hemorrhage. The patent is expected to be valid until 2037.
The United States Patent and Trademark Office has issued a notice of allowance for the Company’s composition of matter patent for GTX-102, a novel, easy-to-use oral mucosal formulation of betamethasone, intended to improve symptoms of ataxia-telangiectasia (A-T). A-T is a progressive, neurodegenerative genetic disease that primarily affects children, causing severe physical disability, for which no treatment currently exists. The patent is expected to be valid until 2037.
The Japanese Patent Office granted a composition of matter patent for the Company’s topical spray GTX-101 targeting postherpetic neuralgia (PHN). PHN is a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles), which may persist for months and even years. GTX-101 could provide significant benefits over the current standard of care including greater convenience, faster onset of action and longer duration of pain relief. The granted patent is valid until 2036.

“We are delighted to announce these latest patent notifications and awards, which dramatically strengthen the intellectual property around Acasti’s three lead programs, GTX-104, GTX-102 and GTX-101,” commented Jan D’Alvise, Chief Executive Officer of Acasti. “These patents extend our IP protection through to at least 2036, and further validate our unique approach to drug development by combining novel drug delivery technologies with established therapies to improve efficacy and safety, increase patient compliance and improve patient outcomes across a variety of rare and orphan diseases. We believe these drug candidates may also have a faster path to regulatory approval and commercialization via the FDA’s 505(b)(2) pathway. We are actively advancing each of these clinical programs and look forward to providing updates on our progress.”